Breast cancer immunotherapy: facts and hopes
LA Emens - Clinical cancer research, 2018 - AACR
Immunotherapy is revolutionizing the management of multiple solid tumors, and early data
have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 …
have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 …
Mechanisms of therapeutic antitumor monoclonal antibodies
Monoclonal antibodies (mAb) are a major component of cancer therapy. In this review, we
summarize the different therapeutic mAbs that have been successfully developed against …
summarize the different therapeutic mAbs that have been successfully developed against …
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L Bracci, G Schiavoni, A Sistigu… - Cell Death & …, 2014 - nature.com
Conventional anticancer chemotherapy has been historically thought to act through direct
killing of tumor cells. This concept stems from the fact that cytotoxic drugs interfere with DNA …
killing of tumor cells. This concept stems from the fact that cytotoxic drugs interfere with DNA …
Combining immunotherapy and targeted therapies in cancer treatment
M Vanneman, G Dranoff - Nature reviews cancer, 2012 - nature.com
During the past two decades, the paradigm for cancer treatment has evolved from relatively
nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer …
nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer …
Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy
Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor-2
(HER2/ErbB-2), has become the mainstay of treatment for HER2-positive breast cancer …
(HER2/ErbB-2), has become the mainstay of treatment for HER2-positive breast cancer …
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen–specific T-cell immunity in head and neck cancer patients
RM Srivastava, SC Lee, PA Andrade Filho… - Clinical Cancer …, 2013 - AACR
Purpose: Tumor antigen–specific monoclonal antibodies (mAb) block oncogenic signaling
and induce Fcγ receptor (FcγR)–mediated cytotoxicity. However, the role of CD8+ CTL and …
and induce Fcγ receptor (FcγR)–mediated cytotoxicity. However, the role of CD8+ CTL and …
The immune system and response to HER2-targeted treatment in breast cancer
G Bianchini, L Gianni - The Lancet Oncology, 2014 - thelancet.com
The monoclonal antibody trastuzumab targets the growth factor receptor HER2 and has
profoundly improved the course of disease and survival of women with HER2 …
profoundly improved the course of disease and survival of women with HER2 …
Tumor antigen–targeted, monoclonal antibody–based immunotherapy: clinical response, cellular immunity, and immunoescape
Purpose Tumor antigen (TA)–targeted monoclonal antibodies (mAb), rituximab,
trastuzumab, and cetuximab, are clinically effective for some advanced malignancies …
trastuzumab, and cetuximab, are clinically effective for some advanced malignancies …
Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells
VA Gall, AV Philips, NA Qiao, K Clise-Dwyer… - Cancer research, 2017 - AACR
Early-phase clinical trials evaluating CD8+ T cell–eliciting, HER2-derived peptide vaccines
administered to HER2+ breast cancer patients in the adjuvant setting suggest synergy …
administered to HER2+ breast cancer patients in the adjuvant setting suggest synergy …
A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell–mediated anticancer activity
In cancers with tumor-infiltrating lymphocytes (TILs), monoclonal antibodies (mAbs) that
block immune checkpoints such as CTLA-4 and PD-1/PD-L1 promote antitumor T-cell …
block immune checkpoints such as CTLA-4 and PD-1/PD-L1 promote antitumor T-cell …